Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NCT01508949 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on weight and appetite in adults who are obese and have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 35 people

Who can join Ages 18+ · all sexes

Timeline Started 2001-06 · est. completion 2002-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01508949 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
placebo Drug

Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously

Main thing measured	Change in weight
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01508949 ↗